PALO ALTO, Calif. & TORONTO--(BUSINESS WIRE)--May 22, 2001-- Agilent Technologies Inc. (NYSE:A - news) and MDS Proteomics, a leading proteomics-based drug discovery company, today announced an agreement to develop new protein analysis technologies and products that are expected to ultimately speed the development of new medicines.
The focus of this collaboration will be on the development of specialized products that speed the process of identifying and analyzing proteins -- critical steps in the process of determining protein interactions in the human gene. Both companies will jointly develop new technologies and applications that enable biotechnology or pharmaceutical companies to accelerate the development of new medicines that will have fewer adverse side effects than today's drugs.
``Agilent has been a leader in understanding protein-separation chemistry for many years,'' said Jeffrey White, vice president and general manager of Agilent's Bio-Consumables and Services. ``MDS Proteomics is recognized as the premier Protein Research organization. When you combine the strength of our separations knowledge with MDS Proteomics' domain expertise, you get a very powerful research team.''
``MDS-Proteomics' relationship with Agilent brings together two world leaders in their fields to develop proprietary solutions that address the front-end sample handling limitations associated with classical expression proteomics,'' said Frank Gleeson, president and CEO of MDS Proteomics. ``In our discovery facilities we are automating an innovative, ultra-sensitive process to functionally annotate and validate the antigen and protein targets of cells in a high-throughput manner. Relationships such as this are designed to ensure that we remain at the forefront of functional proteomics research worldwide.''
The agreement will combine Agilent's expertise in separation science and liquid chromatography -- a protein separation process that helps to speed the identification and characterization of proteins -- and MDS Proteomics' capabilities in protein pathway biology, ultra-sensitive mass spectrometry analysis and high-performance super-computing... |
